Factors to be considered when selecting an optimal sterile prep solution prior to cutaneous surgery include the underlying health status of the patient, the expected extent of the surgery, the anatomic location of the tumor to be removed or planned reconstruction, and the inherent effectiveness of the prep solution. Recently, it has been suggested that different prep solutions may pose varying risks to patients. For instance, 83% of surgical dermatologists use chlorhexidine on the face.
1 On the one hand, it has been suggested that chlorhexidine use may contribute to the very low incidence of infection seen in coldsteel skin surgery and in minimally invasive cosmetic procedures such as filler injections. On the other hand, the ocular risks of chlorhexidine may outweigh the benefits. The purpose of this analysis was to compare the safety and effectiveness of prep solutions for skin surgery of the head and neck.
Methods | Data from a multicenter, prospective cohort study 2 of Mohs micrographic surgery of the head and neck were compared to determine whether different prep solutions were associated with different rates of adverse events, particularly postoperative infection. Unpaired χ 2 test was performed to assess these associations, and 2-sided P = .05 indicated statistical significance. This study was performed under 2 expedited Northwestern University institutional review board protocols, which collectively authorized data collection and managed transmittal of data across institutions to enable analysis. All data collected were deidentified, and patient informed consent was waived per the direction of Northwestern University's institutional review board. Data were collected from November 29, 2010, through April 2, 2012, and were analyzed between October 4, 2016, and January 8, 2017.
Results | The risk of postoperative infection varied on the basis of the surgical prep solution used for Mohs surgery. The Surgical cases pretreated with chlorhexidine sterile prep or 3.0% chloroxylenol (Techni-Care surgical scrub; Care-Tech Laboratories) were associated with the lowest rate of infection (0.06% for both solutions), while those pretreated with povidone iodine were associated with the highest rate (1.3%).
(Techni-Care was recalled in the past because of manufacturing issues and was not available at the time of this writing.) Overall, the infection rate associated with chlorhexidine and Techni-Care was statistically significantly lower (17 459 cases; χ 2 1 = 59.08; P < .001) than the rate associated with all other prep solutions. There were no reports of ocular injury or other adverse events associated directly with the application of any prep solutions.
Discussion | Previously, Mohs micrographic surgery has been shown to be an exceedingly safe procedure, 2-6 with an overall risk of adverse events of less than 1% and a risk of surgeryassociated wound infection of 0.44%. 2 Use of chlorhexidine has been found to be inversely associated with infection risk. However, prior to our study, no large-sample comparative analysis had been performed of the risk of infection associated with different types of prep solutions used in dermatologic surgery.
There are limitations to this study. Most notably, because this was a cohort study and not a randomized clinical trial, there may be unknown confounders affecting the data. However, this study used a large consecutive sample (N = 17 459) and included many centers (23), which increases confidence that physician-specific or center-specific practices did not skew the results. In the future, it would be useful to stratify the obtained results by the type of reconstruction, the anatomic site of the tumor, and patient characteristics, such as immune status. Of note, the extremely low postoperative infection rates observed for chlorhexidine and Techni-Care (0.06% for both solutions) are markedly lower than the previously reported rates, which possibly indicates some patient selection bias in the cohort. Alternatively, the rates we detected may be accurate compared with prior estimates because the large sample we analyzed may be more representative of current clinical practice.
Conclusions | To our knowledge, this study is the first comparison of the clinical effectiveness of prep solutions in a large prospective sample. Moreover, the differences detected are clinically significant in that they confirm that chlorhexidine is a safe and effective prep solution for cutaneous surgery of the head and neck. Further research is required to validate the findings presented. Anti-infective properties of surgical prep solutions are just a single feature that should be considered by physicians when they select an appropriate prep solution for a particular patient. 
OBSERVATION

Occurrence of Acute Cerebellar Syndrome After Topical Application of Fluorouracil
Localized discomfort and phototoxic effects are common adverse effects of topical fluorouracil therapy. When the drug is administered systemically, acute cerebellar syndrome may occur, characterized by headache and ataxia. We report identical transient cerebellar findings from its topical application.
Case Report | A man in his 60s was treated for extensive scalp actinic keratoses with fluorouracil cream applied twice daily, massaging this onto the skin in the morning after showering and onto dry skin each evening. Only minimal scalp tenderness occurred after 2.5 weeks. After 3.5 weeks, the patient experienced severe headaches and awoke in the morning with marked unsteadiness on his feet, altered coordination in gait, and dizziness. No other neurological findings were noted. Diagnostic testing was deferred, and fluorouracil treatment was stopped. All signs and symptoms resolved within 8 hours of treatment cessation without any intervention other than acetaminophen. At last follow-up, 23 months later, he had experienced no recurrence. Dihydropyrimidine dehydrogenase (DPD) deficiency, a known risk factor for fluoropyrimidine toxic effects, was ruled out by DPYD targeted and whole gene sequencing.
Discussion | Fluorouracil was introduced into clinical trials in 1957 for treatment of advanced cancers (colon, rectum, breast, stomach, pancreas). 1 Adverse effects reported included bonemarrow suppression, stomatitis, nausea, vomiting, diarrhea, alopecia, and skin eruptions. Fortuitous observation that actinic keratosis lesions became inflamed as a result of systemic fluorouracil therapy led to its development as a topical treatment.
The first neurological adverse effect of systemic fluorouracil (reversible cerebellar ataxia) was reported in 1964.
2,3
Since then many other neurological complications have been reported, including encephalitis, organic brain syndrome, and subacute multifocal leukoencephalopathy.
3-6 One study 3 found that among 287 consecutive patients treated, 3.1% developed cerebellar ataxia, most commonly presenting as poor balance or unsteadiness of gait. Less frequent adverse events included nystagmus, incoordination of the upper extremities, slurred speech, mild memory loss, slowness of speech, altered taste sensation, paresthesias, weakness, and fatigue. No association was noted between age or sex and the risk or severity of ataxia and the severity of other adverse effects. In some study participants, ataxia did not develop until after several cycles of therapy (median time to onset after first exposure to fluorouracil, 6 weeks; range, 2 weeks to 9 months), and the ataxia then lasted from 1 week to 13 months. 3 In about half the cases, the ataxia resolved and did not recur despite further chemotherapy. Other reports have confirmed the rarity of ataxia arising from systemic fluorouracil (range of incidence, 1%-0.16%).
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To our knowledge, there has never been a reported case of cerebellar ataxia secondary to topical fluorouracil therapy. Familial deficiency of dihydropyrimidine dehydrogenase (DPD), the initial enzyme involved in pyrimidine catabolism, accounting for 80% of the metabolism (hepatic; renal) of fluorouracil, increases the risk of severe neurological toxic effects. In one series of cancer patients, prevalence of DPD deficiency was found to be 2.7%. 6 The risk and severity of ataxia is probably influenced by peak plasma level, not cumulative dose of fluorouracil.
3
To our knowledge, this is the first report of neurological adverse events following topical treatment with fluorouracil that are identical to those seen with systemic therapy. Given the rarity of ataxia with high-dose systemic fluorouracil, the low prevalence of DPD deficiency within the population, and
